Health-related quality of life outcomes in PARAGON-HF.

Alvin Chandra,Carisi A Polanczyk,Brian L Claggett,Muthiah Vaduganathan,Milton Packer,Martin P Lefkowitz,Jean L Rouleau,Jiankang Liu,Victor C Shi,Heike Schwende,Michael R Zile,Akshay S Desai,Marc A Pfeffer,John J V McMurray,Scott D Solomon,Eldrin F Lewis

European journal of heart failure（2022）

引用 5|浏览10

暂无评分

摘要

Compared with valsartan, sacubitril/valsartan had a borderline benefit on KCCQ-CSS at 8 months in patients with HFpEF. This benefit became more significant when data from all visits up to 36 months were included. This modest overall benefit was also supported by greater odds of patients reporting a clinically meaningful improvement in HRQL with sacubitril/valsartan.

查看译文

关键词

Health-related quality of life,Heart failure with preserved ejection fraction,Neprilysin inhibitor,Randomized clinical trial,Sacubitril/valsartan

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要